Home > Insider Trading > Filing (0000947871-10-000524)

Filing Details

Accession Number:: 0000947871-10-000524
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-04-26 13:00:00
Reporting Period:: 2009-04-30

Filing Date:: 2010-04-26
Accepted Time:: 2010-04-26 11:52:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1061027	Sunesis Pharmaceuticals Inc	SNSS	Pharmaceutical Preparations (2834)	943295878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1486952	Dominique Semon	424 West 33Rd Street, Ste 520 New York NY 10001		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2009-12-11	1,508,051	$2.02	0	No	4	S	Indirect	See footnotes
Common Stock	Acquisiton	2010-02-25	3,398,300	$0.22	3,398,300	No	4	X	Indirect	See footnotes
Common Stock	Disposition	2010-02-25	793,803	$0.94	2,604,497	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes
No	4	X	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Preferred Stock	Options	Acquisiton	2009-04-30	169,914	$0.00	169,914	$2.20
Warrants	Options	Acquisiton	2009-04-30	1,699,140	$0.00	1,699,140	$0.00
Common Stock	Warrants	Acquisiton	2009-04-30	3,398,300	$0.13	3,398,300	$0.22
Preferred Stock	Options	Disposition	2009-10-27	169,914	$0.00	169,914	$2.20
Warrants	Options	Disposition	2009-10-27	1,699,140	$0.00	1,699,140	$0.00
Common Stock	Warrants	Acquisiton	2009-10-27	1,699,140	$0.00	1,699,140	$0.22
Common Stock	Preferred Stock	Acquisiton	2009-10-27	169,914	$2.20	1,699,140	$2.20
Common Stock	Warrants	Disposition	2010-02-25	3,398,300	$0.13	3,398,300	$0.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
169,914	2009-04-30	2016-04-03	No	4	P	Indirect
1,699,140	2009-04-30	2016-04-03	No	4	P	Indirect
3,398,300	2009-04-30	2016-04-03	No	4	P	Indirect
0	2009-04-30	2016-10-31	No	4	X	Indirect
0	2009-04-30	2016-10-31	No	4	X	Indirect
5,097,440	2010-10-27	2016-10-31	No	4	X	Indirect
509,744	2010-10-27		No	4	X	Indirect
1,699,140	2009-04-30	2016-04-03	No	4	X	Indirect

Footnotes

On December 11, 2009 Nexus Gemini L.P. ("Gemini") and Merlin Nexus II, L.P. ("Nexus II") sold 1,000,000 and 508,051 shares of Common Stock, respectively.
The Reporting Person is the managing member of Nexus Gemini Advisors, LLC and Merlin Biomed Private Equity Advisors, LLC, the investment advisors to Gemini,Nexus II, and Merlin Nexus III, L.P. ("the Funds"). The Funds own direct interests in the reported securities.
The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
On April 30, 2009 Gemini and Nexus III acquired 1,399,300 and 1,999,000 warrants respectively. Each warrant was exercisable to purchase one share of commonstock. On February 25, 2010 Gemini and Nexus III exercised 1,399,300 and 1,999,000 warrants, respectively, and thereby acquired 1,399,300 and 1,999,000shares of common stock, respectively. Also on February 25, 2010, Gemini and Nexus III sold 326,860 and 466,943 shares of common stock, respectively.
On April 30, 2009 Gemini and Nexus III acquired options to purchase preferred stock and warrants. Gemini's option allowed it to purchase 69,964 shares of preferredstock, each convertible into 10 shares of common stock, and 699,640 warrants, each exercisable to purchase one share of common stock. Nexus III's option allowedit to purchase 99,950 shares of preferred stock, each share convertible into 10 shares of common stock, and 999,500 warrants, each exercisable to purchase oneshare of common stock. On October 27, 2009 Gemini and Nexus III exercised their options to acquire, respectively, 699,640 and 999,500 warrants and 69,964 and99,950 shares of preferred stock.
No Expiration Date for these Preferred Shares.